How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Closed-loop Automated Insulin Delivery (AID) System Market
- By System Type: Hybrid Closed-Loop Systems, Fully Closed-Loop Systems, Predictive Low Glucose Suspend Systems, Automated Insulin Delivery with Meal Announcement, Dual-Hormone Closed-Loop Systems
- By Component Type: Continuous Glucose Monitor (CGM), Insulin Pump, Control Algorithm Software, Mobile Application Interface, Data Management Platform
- By End User: Pediatric Patients, Adult Patients, Geriatric Patients, Pregnant Women with Diabetes
- By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Online Pharmacies, Retail Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hybrid Closed-Loop Systems leads By System Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Closed-loop Automated Insulin Delivery (AID) System Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
System Type 5
Component Type 5
End User 4
Distribution Channel 4
Companies profiled
Medtronic
Insulet Corporation
Tandem Diabetes Care
Roche Diabetes Care
Dexcom
Abbott Laboratories
Beta Bionics
Bigfoot Biomedical
Eli Lilly and Company
Sanofi
Novo Nordisk
Ascensia Diabetes Care
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Insulet Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Tandem Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Roche Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Dexcom
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Beta Bionics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bigfoot Biomedical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Novo Nordisk
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ascensia Diabetes Care
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Senseonics Holdings
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Glooko
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ypsomed
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,284M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hybrid Closed-Loop Systems40.9
- Fully Closed-Loop Systems10.9
- Predictive Low Glucose Suspend Systems16.1
- Automated Insulin Delivery with Meal Announcement21.1
- Dual-Hormone Closed-Loop Systems11.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,632M → $2,558M · 5.8%
Europe$1,138M → $1,708M · 5.2%
Asia Pacific$1,039M → $1,625M · 5.8%
Latin America$642.9M → $1,030M · 6.1%
Middle East and Africa$494.6M → $752.5M · 5.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.902026
4.922027
4.932028
4.942029
4.972030
4.962031
4.982032
4.992033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic23.6
- Insulet Corporation11.2
- Tandem Diabetes Care14.5
- Roche Diabetes Care4.8
- Dexcom12.8
- Abbott Laboratories5.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →System Type32.8%
Component Type12.5%
End User22.6%
Distribution Channel32.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe22.3
- Asia Pacific21.2
- Latin America13.4
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 87 | 75 | 75 | 89 | 80 | 91 | 83 |
| Insulet Corporation | 77 | 85 | 73 | 81 | 84 | 76 | 79 |
| Tandem Diabetes Care | 82 | 68 | 80 | 87 | 84 | 67 | 78 |
| Roche Diabetes Care | 59 | 73 | 67 | 78 | 58 | 74 | 68 |
| Dexcom | 67 | 58 | 71 | 62 | 74 | 77 | 68 |
| Abbott Laboratories | 53 | 59 | 70 | 48 | 63 | 49 | 57 |
| Beta Bionics | 56 | 43 | 57 | 50 | 56 | 41 | 51 |
| Bigfoot Biomedical | 43 | 36 | 47 | 53 | 36 | 53 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Insulet Corporation
- Tandem Diabetes Care
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Insulet Corporation | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Tandem Diabetes Care | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Roche Diabetes Care | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Dexcom | ✓ | − | ◐ | − | ◐ | ✓ |
| Abbott Laboratories | − | ◐ | − | ◐ | − | − |
| Beta Bionics | − | − | ◐ | − | − | − |
| Bigfoot Biomedical | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic83
2Insulet Corporation79
3Tandem Diabetes Care78
4Roche Diabetes Care68
5Dexcom68
6Abbott Laboratories57
7Beta Bionics51
8Bigfoot Biomedical45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
MedtronicInsulet CorporationTandem Diabetes Care
Challenger2
Strong scale, closing on the leaders.
Roche Diabetes CareDexcom
Contender1
Focused players with pockets of strength.
Abbott Laboratories
Niche2
Specialists in a single segment or region.
Beta BionicsBigfoot Biomedical
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land System Type in North America, then scale across Closed-loop Automated Insulin Delivery (AID) System Market — a $261M beachhead inside a $4.64B market.
Beachhead (SOM)$261Mobtainable near-term
Serviceable (SAM)$1.83Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Hybrid Closed-Loop Systems
Best fit — highest urgency & budget in System Type.
Economic buyer79 fit
Fully Closed-Loop Systems
Strong fit — clear ROI and a fast path to value.
End user68 fit
Predictive Low Glucose Suspend Systems
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win System Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Component Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For System Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Closed-loop Automated Insulin Delivery (AID) System Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified20%
Evaluation13%
Closed-won6%
$21.5KCAC
$109KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Closed-loop Automated Insulin Delivery (AID) System Market is a resilient opportunity — $6.14B by 2033, compounding at 4.6%.
TAM · 2025$4.28Btoday
TAM · 2033$6.14Bforecast
CAGR4.6%2027–2033
Cumulative$46.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.14BTotal addressable market
SAM$2.21BServiceable available market
SOM$433MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.6% CAGR
Demand compounds through 2033, outpacing GDP across System Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in System Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.14BLarge & growingTAM by 2033 at 4.6% CAGR
$2.21BServiceable nowreachable with today’s model
$433MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.79BBear3.0% CAGR
$6.14BBase4.6% CAGR
$7.86BBull6.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Component Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Closed-loop Automated Insulin Delivery (AID) System Market — a $603M market by 2033. Plan: grow share from 6.9% to 13.6%.
Market size · 2033$603Mtotal addressable
Market CAGR3.6%2027–2033
Target share13.6%from 6.9% today
Revenue ambition$82Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 13.6% | Ahead |
| Revenue | $44M | $82M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.2% | 38.7% | At risk |
| Customer retention | 86.8% | 93.8% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in System Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Component Type capability
A defensible second engine — invest in Component Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core System Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Component Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $9M capacity & capability investment
- Greenlight bolt-on M&A in Component Type
- Authorise North America expansion plan
- Fund R&D program for System Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Closed-loop Automated Insulin Delivery (AID) System Market conversation — a $7.88B market you can size, segment and defend in minutes.
Market size · 2033$7.88Btotal opportunity
Growth8.2%CAGR to 2033
Addressable buyers1,600+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of System Type
Goal Grow share in System Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 3 mopayback period
$90K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
MedtronicInsulet CorporationTandem Diabetes CareRoche Diabetes CareDexcomAbbott LaboratoriesBeta BionicsBigfoot Biomedical+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Closed-loop Automated Insulin Delivery (AID) System Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Closed-loop Automated Insulin Delivery (AID) System Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Closed-Loop Hall Effect Current Sensors Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportClosed-Loop Wastewater Treatment System Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportClosed-Vessel Ultraviolet Disinfection Equipment Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportClose-In Weapon Systems Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportClosestool Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCloset Air-Conditioning Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCloset Organizer App Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCloset Organizers Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportCloset Storage & Organization Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportClose-up Lens Filter Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportClosing Machine Market
Market size, share, segmentation and regional forecast.
$627M market · 2025 base year
View reportClosing Rib Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.